J
J. Fernando Arevalo
Researcher at Johns Hopkins University School of Medicine
Publications - 337
Citations - 7532
J. Fernando Arevalo is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Visual acuity & Vitrectomy. The author has an hindex of 41, co-authored 307 publications receiving 6568 citations. Previous affiliations of J. Fernando Arevalo include Johns Hopkins Bayview Medical Center & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Lihteh Wu,Maria Ana Martinez-Castellanos,Hugo Quiroz-Mercado,J. Fernando Arevalo,Maria H. Berrocal,Michel Eid Farah,Mauricio Maia,Jose A. Roca,Francisco Rodríguez +8 more
TL;DR: Repeated intravitreal injections of either 1.25 mg or 2.5 mg of bevacizumab appears to be safe and well tolerated during the 1st year despite the limited follow-up, according to this retrospective, multicenter, open label, uncontrolled interventional case series.
Journal ArticleDOI
Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
J. Fernando Arevalo,Jans Fromow-Guerra,Hugo Quiroz-Mercado,Juan G. Sanchez,Lihteh Wu,Mauricio Maia,Maria H. Berrocal,A. Solis-Vivanco,Michel Eid Farah +8 more
TL;DR: Primary intravitreal bevacizumab at doses of 1.25 to 2.5 mg seem to provide stability or improvement in VA, OCT, and FA in DME at 6 months, and results appear promising.
Journal ArticleDOI
Endophthalmitis after 25-gauge and 20-gauge pars plana vitrectomy: Incidence and outcomes
Ingrid U. Scott,Harry W. Flynn,Sundeep Dev,Saad Shaikh,Robert A. Mittra,J. Fernando Arevalo,Andrés Kychenthal,Nur Acar +7 more
TL;DR: Endophthalmitis after 25-gauge PPV occurred within 15 days of PPV, was usually due to coagulase-negative staphylococci sensitive to vancomycin, and was associated with variable visual outcomes.
Journal ArticleDOI
Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.
Manuel Díaz-Llopis,David Salom,Carmen Garcia-de-Vicuña,Miguel Cordero-Coma,Gabriela Ortega,Norberto Ortego,Marta Suarez-de-Figueroa,Maria J. Rio-Pardo,Carlos Fernandez-Cid,Alex Fonollosa,Ricardo Blanco,Ángel García-Aparicio,José Benítez-del-Castillo,Jose Luis Olea,J. Fernando Arevalo +14 more
TL;DR: Adalimumab seems to be well tolerated and helpful in decreasing inflammatory activity in refractory uveitis and may reduce steroid requirement.
Journal ArticleDOI
Photodynamic therapy for chronic central serous chorioretinopathy.
José M. Ruiz-Moreno,Francisco Lugo,Félix Armadá,Rufino Silva,Javier A. Montero,J. Fernando Arevalo,Luis Arias,Francisco Gómez-Ulla +7 more
TL;DR: This study aimed to evaluate the efficacy of photodynamic therapy (PDT) in treating chronic central serous chorioretinopathy (CSC) and found it to be effective in treating CSC.